New drug shows promise for rare kidney disease
NCT ID NCT06513338
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tested a drug called eculizumab in 16 people with anti-GBM disease, a severe autoimmune condition that often leads to kidney failure. The drug blocks a part of the immune system believed to cause kidney damage. Researchers measured how many patients avoided dialysis or kidney transplant, and tracked kidney function changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Eculizumab (a drug that blocks a part of the immune system called complement C5)
What this could lead to
If it works, this could offer a new treatment option for anti-GBM disease, potentially reducing the need for dialysis or kidney transplant.
What could go wrong
This is a small, early-phase trial with only 16 people, so results may not apply to everyone. The drug also increases risk of serious infections like meningitis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Beijing, 100038, China